Editor Name: Michael R Hamblin
Designation: Associate Professor
University: Harvard Medical School
Michael Hamblin is a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital, an Associate Professor of Dermatology at Harvard Medical School and a member of the Affiliated Faculty of Harvard-MIT Division of Health Science and Technology. He was trained as a synthetic organic chemist and received his PhD from Trent University in England. He joined Wellman Labs in 1994. He worked initially in targeted photodynamic therapy (PDT) and prepared and studied conjugates between photosensitizers and antibodies or targeted proteins and polymers of varying charge. Dr. Hamblin has published over 289 peer-reviewed articles, over 150 conference proceedings, book chapters and international abstracts, and he holds eight patents. Dr. Hamblin has developed an interest in elucidating the basic molecular and cellular mechanisms of LLLT, and for the past eleven years has chaired an annual conference at SPIE formerly entitled "Mechanisms for Low Level Light Therapy" and now called "Mechanisms for Photobiomodulation" and has co-edited the 11 Proceedings of SPIE volumes associated with these conferences. He is Associate Editor of 7 International Journals including Photochemistry and Photobiology, PLoS ONE, Photodiagnosis and Photodynamic Therapy and Journal of Nanomedicine and Nanotechnology. He is on the editorial boards of a further 15 journals and has peer-reviewed for a total of 165 journals. He has served on numerous study sections and grant-reviewing panels and is on the scientific advisory boards of several companies.